Autoradiograph

Ashvattha Therapeutics Announces Preclinical Data on Hydroxyl Dendrimer Based PET Tracer [18F]OP-801 Presented at the 2022 World Molecular Imaging Congress

Retrieved on: 
Thursday, September 29, 2022

REDWOOD CITY, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel hydroxyl dendrimer therapeutics, today announced preclinical data presented by collaborators from Stanford University demonstrating that its hydroxyl dendrimer (HD)-based PET tracer, [18F]OP-801, can detect activated macrophages and microglia with high sensitivity and specificity in an experimental autoimmune encephalomyelitis (EAE) murine model of multiple sclerosis (MS), in addition to being reproducibly synthesized and suitable for human use. The data were presented at the World Molecular Imaging Congress being held September 28th – October 1st, 2022, at the Miami Beach Convention Center in Miami, FL.

Key Points: 
  • The data were presented at the World Molecular Imaging Congress being held September 28th October 1st, 2022, at the Miami Beach Convention Center in Miami, FL.
  • PET imaging data was corroborated by autoradiography images, showing significantly higher signal in the lumbar spinal cord of untreated compared to treated EAE mice.
  • Human dosimetry estimates based on mouse imaging data are conducive to translation and clinical imaging of [18F]OP-801.
  • Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammation and neuro-oncology.

Stefan Linehan Promoted to Vice President of Operations and Development at TissueVision, Inc.

Retrieved on: 
Wednesday, March 30, 2022

TissueVision, Inc., a leading provider of life sciences imaging solutions, announced today the promotion of Stefan Linehan to Vice President of Operations and Development.

Key Points: 
  • TissueVision, Inc., a leading provider of life sciences imaging solutions, announced today the promotion of Stefan Linehan to Vice President of Operations and Development.
  • In his new role, Linehan will expand TissueVisions service offerings through strategic partnerships with clients and industry organizations.
  • He will continue to oversee sales and growth of TissueVisions Serial Two-Photon Plus (STP2) imaging and solutions platform.
  • Previously, Linehan oversaw mass spectrometry imaging (MSI) services as Director of North America and Head of Japan at ImaBiotech.

Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286

Retrieved on: 
Thursday, October 7, 2021

This is representative of our commitment to emerge as a leader in targeted radionuclide therapy by developing innovative radiotherapies such as FAP-2286 for patients with hard-to-treat cancers.

Key Points: 
  • This is representative of our commitment to emerge as a leader in targeted radionuclide therapy by developing innovative radiotherapies such as FAP-2286 for patients with hard-to-treat cancers.
  • To determine FAP protein expression in different tumor types, a pan-tumor IHC screen was performed that included 360 samples representing 16 different tumor types.
  • FAP-2286 is a clinical candidate under investigation as a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP).
  • LuMIERE is a Phase 1/2 study evaluating FAP-2286 as a peptide-targeted radionuclide therapy (PTRT) targeting fibroblast activation protein, or FAP, in patients with advanced solid tumors (NCT04939610) .